Abstract: An eye drops composition containing estradiol-17beta dissolved therein or in a crystalline form, said composition being suitable for treating chronic catarrh disorders of the ocular conjunctiva, that is chronic conjunctivitis simplex.

Abstract: The invention relates to new arylazo compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 independently of each other represent hydrogen or C.sub.1-3 alkyl, R.sub.3 represents hydrogen, halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, carboxy, C.sub.1-3 alkoxycarbonyl, C.sub.1-3 alkylcarbonyl or a group X--NH--SO.sub.2 --, wherein X represents a heterocyclic ring, R.sub.4 represents hydrogen, halogen or C.sub.1-3 alkyl, and n is the integer 1 or 2, the two groups ##STR2## being the same or different when n is 2, and lactones and salts thereof. The compounds of formula I have a high inhibiting effect on prostaglandin synthetizing and inactivating enzymes and may therefore be used as a drug and anti-fertility agent. The invention also relates to preparation of the compounds of formula I as well as pharmaceutical compositions containing the same.

Abstract: A method for determining the alcohol consumption of an individual by means of quantifying isotransferrin combinations in the individual's body fluids, these combinations being (A) isotransferrins having a pI higher than 5.6 or (B) isotransferrins having a pI higher than 5.8 or (C) isotransferrins having a pI higher than 6.0. The total concentration of any of said combinations (A), (B), (C) is a measure of the said individual's alcohol consumption during the last few weeks.

Abstract: The present invention is concerned with a process and apparatus for generating back pressure in a liquid chromatography system, in that the eluent after having passed through the detector cell is caused to pass through a valve, said valve generating a back pressure and having for this purpose a passage (A-B) which is formed, at an interface between two bodies (20, 24), only when a sufficiently high liquid pressure has been attained, at least one of said bodies being a body of an elastic material.

Abstract: The present invention is concerned with compounds having a pharmaceutically acceptable degree of purity, and with formulations of these compounds for the treatment of inflammatory disorders in the intestine (IBD), especially ulcerative colitis. These compounds are 4,5'-azo-bis-salicylic acid (I) and its pharmaceutically acceptable salts, especially the disodium salt. The invention is also concerned with a method for treating inflammatory conditions in the intestine, especially ulcerative colitis. Finally the invention also comprises a method of producing 4,5'-azo-bis-salicylic acid with a pharmaceutically acceptable degree of purity.

Abstract: The invention relates to a new polymer containing quarternary amino group based on dextran or cross-linked dextran. The quarternary amino groups are of the formula ##STR1## where R.sub.1, R.sub.2 and R.sub.3, which may be identical or different, are lower alkyl groups of 1-5 carbon atoms or lower hydroxyalkyl groups of 2-5 carbon atoms and 1-2 hydroxy groups. At most one atom other than carbon and hydrogen is bound to the same carbon atom in the hydroxy alkyl group.

Abstract: The invention is concerned with purification of a biologically active substance with the aid of a system of at least two immiscible aqueous phases; the process of the invention involves binding said substance to particles which have an affinity for said substance and distribute predominantly quantitative into one of said phases, and subsequently liberating said substance from said particles after separating the particle-containing phase from the other phase or the other phases.

Abstract: A method of treating inflammatory diseases such as ulcerous colitis, comprising administration of 3,3'-azo-bis-(6-hydroxy benzoic acid) of the formula: ##STR1## or pharmaceutically acceptable salts thereof. Pharmaceutical compositions, especially for oral administration, contain said compound, or pharmaceutically acceptable salts thereof, together with pharmaceutically acceptable carriers and/or adjuvants.

Abstract: In the formation of polymeric layers, especially anisotropic polymeric layers, on a solid substrate on which the layer is formed by cross-linking of an organic substance which can be cross-linked, the cross-linking is performed in a manner such that a concentration gradient of at least one of the components controlling the cross-linking reaction is formed in the boundary layer between the substrate to be coated and the surrounding solution, which concentration gradient is adjusted so that cross-linking can take place in the boundary layer but not in the surrounding solution. The concentration gradient is preferably achieved by impregnating the substrate with at least one of the components which control the cross-linking reaction and which tends to diffuse into the solution on contact therewith.

Abstract: A method of preparing 3,3'-azo-bis-(6-hydroxy benzoic acid) of formula I ##STR1## and salts thereof in at least 98% purity for treating inflammatory intestinal diseases. According to the invention a compound II ##STR2## is diazotized, and the diazonium salt obtained is coupled with a compound III ##STR3## The formed intermediate IV, which is also comprised by the invention, ##STR4## is hydrolized in alkaline medium to form the compound I. R.sub.1, R.sub.2 and R.sub.3 signify lower alkyl, R.sub.2 also possibly substituted phenyl.

Abstract: A closure device for fluid-tight closure of an opening of a fluid container. The device comprises a casing part (1) and a cap part (2). These parts are injection molded from different plastic materials, preferably from PVC and polypropylene, respectively, one partially against the other. A tubular portion (12) of the cap part (2) intrudes sealingly into a substantially cylindrical hollow space between an internal and an external sleeve portion (3,4) of the casing part (1).

Abstract: A device for treating samples, for example collection of fractions from a chromatographic separation process, comprises a series of test containers (11), a treatment unit (5) and an apparatus (4) for creating relative motion between the test containers and the treatment unit. The treatment unit passes the test containers in sequence and subjects the same to one or more treatment steps. According to the invention the test tubes are detected and their position indicated by a sensor (9) which is arranged to trigger the treatment step or steps when contacting a given area on the respective test container (11), especially by the resilient biasing of a spring (13).

Abstract: This invention pertains to allergen-containing substances, methods of preparing the same and using the same as immunologically specific suppressants of the production of reaginic antibodies directed to the allergen in question. The allergen-containing substances can be characterized as covalent conjugates of the allergen molecules with non-immunogenic water-soluble polymers. The degree of conjugation is such that the conjugates are rendered tolerogenic as well as substantially non-allergenic and non-immunogenic. The new conjugates are useful for immunologically specific suppression of common allergies in mammals, including humans, which are mediated by reaginic antibodies of the IgE class.

Abstract: The present invention concerns an in vitro method for the determination of the plasma inhibitor to activated Factor X (XaI), which is an alpha-2-globulin of molecular weight 58,000-65,000, and which has been termed variously as antithrombin III, heparin cofactor and alpha-2-antitrypsin.

Abstract: A process comprising contacting particles of water insoluble polymers to which have been bound antibodies, by means of covalent bonds, against the protein or polypeptide to be determined, wherein a certain quantity of the protein or polypeptide is labeled with a radioactive isotope, whereupon the particles, subsequent to the reaction between the protein or the polypeptide and the antibodies attached to the particles are separated from the sample liquid and the radioactivity of the particle material and/or in the liquid is determined.

Abstract: Method for determining vitamin B.sub.12 in aqueous samples by contacting said sample with radioactivity labelled vitamin B.sub.12 and with particles of water insoluble polymers to which substances capable of binding vitamin B.sub.12 have been bound, thereafter separating said particles and determining the radioactivity.